3 October 2019 - Three drug manufactures broke competition law by colluding to illegally boost the price of a vital drug at the expense of the NHS, the competition watchdog said on Thursday.

The UK’s Competition and Markets Authority said South African drug company Aspen broke EU competition law by bribing two other rivals to stay out of Britain, maintaining Aspen’s monopoly on fludrocortisone acetate tablets. 

These tablets are used to treat Addison’s disease, a condition where the adrenal glands don’t produce enough steroids. Symptoms include lack of appetite, weakness, and poor mood. The condition affects around 8,400 people in the UK, according to the NHS.

Read Yahoo News article